Asian Pacific Journal of Cancer Prevention, Vol 21

RESEARCH ARTICLE

Genetic Polymorphism of Epidermal Growth Factor Gene as a Predictor of Hepatocellular Carcinoma in Hepatitis C Cirrhotic Patients

Ibrahim Baghdadi1, Khaled Abu Ella2, Ahmed El Shaarawy3, Elsayed Elshayb4, Hala S El-Rebey4, Mohamed M El Hoseeny5, Mary Naguib7, Ali Nada6*

Abstract

Background: In Egypt, the incidence of hepatocellular carcinoma (HCC) is approximately 4.7% of chronic liver disease patients due to (HCV) infection. Epidermal growth factor (EGF) plays an important role in hepatocyte regeneration. A functional polymorphism in EGF 61A>G was identified; it was associated with higher risk of HCC. Objectives: to investigate the correlation between the epidermal growth factor (EGF) polymorphism and the risk of hepatocellular carcinoma (HCC) in hepatitis C viral (HCV) cirrhotic patients as well as its relation to EGF protein expression in HCC tissue. Patients and methods: this casecontrol study was conducted on 75 HCV cirrhotic patients including 50 HCC patients (25 withresectable HCC and 25 with advanced unresectable HCC) and 25 healthy persons were included. EGF genotype was detected by restriction fragment length polymorphism. EGF expression in HCC tissue biopsies from patients who underwent surgical resection was done by immunohistochemical examination. Results: The GG genotype was associated with significant increased risk of HCC compared to AA genotypes (P=0.031) in cirrhotic group. The G allele had a highly significant risk of HCC compared to allele A in recessive model GG vs. AG+AA (P=0.036) rather than in the dominant model GG +AG vs. AA (P=0.66). There was significant increased expression of EGF in tumour tissues in patients with GG genotype compared to AG genotype and AA genotype p= 0.019. Conclusion: EGF gene polymorphism (GG genotype) had a significant risk of HCC development in cirrhotic patients. This is confirmed by increased EGF expression in liver tumor tissue from HCC patients.

Keywords: Epidermal growth factor gene polymorphism- Hepatocellular Carcinoma- Hepatitis C Virus

Introduction

Hepatocellular carcinoma (HCC) is the fifth most common cancer and the third leading cause of cancer deaths worldwide (Thrift et al., 2017). Risk factors vary widely in different geographic regions worldwide (Lavanchy and Kane, 2016). In Egypt hepatitis C virus (HCV) infection is a main cause as Egypt has high prevalence of HCV infection where viremia was reported as 7.3% (Waked et al., 2014). Diagnosis of HCC patients occur at the late stage, allowing only minority of the patients to be candidates for possible curative treatments (Li et al., 2010). Pathogenesis of HCC usually correlates with the presence of continuous inflammation and hepatocyte regeneration associated with chronic hepatitis and hepatic cirrhosis (Ringelhan et al., 2018). Genetic factors also have an important role in HCC pathogenesis (Yuan et al., 2013).

Therefore, studying different biomarkers associated with the increased risk of HCC would allow better screening of highrisk populations for HCC and help to improve prevention and treatment (Li et al., 2010).

Epidermal growth factor (EGF) plays a significant role in cell proliferation, differentiation and tumorigenesis of epithelial tissues (Zhong et al., 2012). The EGF 61A>G polymorphism (rs4444903) is a functional SNP in the 5’ untranslated region of the EGF gene (Xu et al, 2010, Zhang et al., 2010). It results in higher EGF levels in individuals with EGF genotype G/G in comparison to the A/A genotype (Almeida et al., 2010).

Previous studies have shown that EGF rs4444903 SNP could result in increased risk of tumorigenesis in HCC (Zhong et al., 2012). However, other studies have indicated that there is no significant association (Qi et al.,...
Thus, we aimed to detect the correlation between EGF gene polymorphism and risk of HCC in Egyptian HCV cirrhotic patients. Also validate EGF protein expression in HCC tissue related to this polymorphism.

Materials and Methods

Patients and methods

Study population

This case-control study included 75 patients and 25 healthy individuals matched in age and sex as a control group. Patients were recruited from HCC Clinic, Hepatology Unit, National Liver Institute, Menoufiya University in the duration between February 2017 and February 2018. Study was conducted according to the Declaration of Helsinki. All participants provided written informed consent, and the Ethics Committee of National Liver Institute, Menoufiya University approved the study protocol.

Adult cirrhotic HCV patients (> 18 years) were eligible to the study. Diagnosis of cirrhosis was done by clinical evaluation, laboratory investigations and abdominal ultrasonography (US). Patients were classified according to abdominal US, abdominal tri-phasic computed tomography (CT) and serum alpha fetoprotein (AFP) level into HCC patients and cirrhotic patients with no evidence of HCC.

HCC patients were grouped to patients with surgical resectable HCC and patients with advanced unresectable HCC (Multicentric hepatic focal lesions with and/or portal vein thrombosis). Healthy persons, age and sex matched, were enrolled as control group (they were clinically free with normal laboratory investigations, normal abdominal ultrasonography, and no history of liver disease).

Patients with hereditary hepatic diseases, autoimmune liver disorders, other liver cancers, liver disease other than HCV and history of radiological intervention for management of HCC were excluded.

Laboratory investigations

Routine laboratory investigations

Liver, renal function tests and random blood sugar were performed on Cobas 6000 auto analyser (Roche diagnostics- GmbH, D-68305 Mannheim, Germany), prothrombin concentration and international normalized ratio (INR) on BFT II Analyzer (Dade Behring Marburg GmbH, D-35041 Marburg, Germany) and serum alpha fetoprotein level on Cobas e411 immunoassay analyser (Roche diagnostics- GmbH, D-68305 Mannheim, Germany).

Specific investigations

1) DNA extraction and EGF genotyping:

Genomic DNA was extracted from venous blood sample using Zymo Quick-gDNA™ MiniPrep DNA Purification Kit (Zymo Research, CA, USA). The EGF 61A > G Polymorphism (rs4444903) was detected using polymerase chain reaction and restriction fragment length polymorphism (PCR- RFLP) as previously described (Amend et al., 2004; Suenaga et al., 2013).

PCR amplification of EGF was performed using 1μL of each of the following primers: Forward: 5’-TGTCACTAAAGGAAGAGGTT-3’ and reverse 5’-TTCAAGAGTTTACAGCCC-3’ in the following reaction mixture: 12.5 μL of MyTaq™ Red Mix master mix (Bioline, MA, USA), 5.5 μL of nuclelease-free Water and 5 μL of extracted DNA. Amplification occurred through the following conditions: initial denaturation at 95°C for 5 minutes, followed by 35 cycles; 95°C for 45 seconds, 51°C for 45 seconds, 72°C for 45 minute and final extension step of 10 minutes at 72°C using Perkin Elmer Gene Amp PCR System 2400 Thermal Cycler. The successful amplification of a 242 bp region of the EGF 61A > G Polymorphism was confirmed using 3% agarose gel electrophoresis.

Then 10 μL DNA amplification product was digested with 1 μL Fast Digest AluI restriction enzyme (New England Biolabs) for 5-15 min at 37°C. Digestion of the 61*A allele produced 15, 34, and 193 bp fragments, while digestion of the 61*A allele produced 15, 34, 91, and 102 bp fragments.

Detection of EGF in HCC tissue of patients underwent liver resection

Two biopsies were taken from each patient in resectable HCC group, one from neoplastic liver tissue and another from adjacent non-neoplastic tissue. Both stained with hematoxylin and eosin (H and E) were examined under the light microscope to confirm the diagnosis of HCC of the neoplastic liver tissue and cirrhosis of the adjacent non-neoplastic tissue.

Then stained immunohistochemically for EGF expression by streptavidin-biotin amplified System. EGF expression was considered positive when > 5% of the cells showed cytoplasmic brown staining. H score was applied to evaluate the studied cases according to (Bilalovic et al., 2004), where both intensity (scored 1-3 as 1=mild, 2=moderate and 3=strong) and percentage of positive cells were considered.

The intensity score is multiplied by the percentage of cells which stain with each level of intensity, and the sum of these mathematically products is expressed as H score.

H score formula= strong intensity (3) x percentage + moderate intensity (2) x percentage + mild intensity (1) x percentage.

Statistical analysis

Results were statistically analyzed by using statistical package of social sciences (SPSS 22.0, IBM/SPSS Inc., Chicago, IL). Categorical data were presented as number and percentage while quantitative data were expressed as mean and standard deviation. Comparison of continuous data between more than two groups was made by using one way ANOVA for parametric data and Kruskal-Wallis test for nonparametric data with post-tests (Turkey and Dunn test, respectively). Chi square test was used for comparison between Categorical data. P-value < 0.05 was considered significant.
Results

Characteristics of the studied subjects

This study included 75 HCV related cirrhotic patients; 25 (33.3%) patients with surgical resectable HCC, 25 (33.3%) patients with advanced unresectable HCC and 25 (33.3%) cirrhotic HCV patients with no evidence of HCC, also 25 subjects were enrolled as control group. HCC, cirrhotic patients and controls had similar age and gender distribution. They were mostly male (82%, 72% and 64% respectively, p= 0.219) (Table 1).

We couldn’t detect significant difference between HCC group and cirrhotic patients group regarding liver and kidney function tests. However, AFP was significantly higher in HCC group compared to cirrhotic patient group. On the other hand, HCC patients showed significantly elevated ALT, AST, total bilirubin, INR, urea levels and significantly decreased level of albumin compared to control group (Table 2).

Table 2. Statistical Analysis Ofbiochemical Lab Parameters in HCC, Cirrhosis and Control Groups

| Biochemical parameters | HCC (n = 50) | Cirrhosis (n = 25) | Control (n = 25) | Significance test | P-value |
|------------------------|-------------|--------------------|-----------------|------------------|---------|
| ALT (U/L)              | Median (IQR) | 63.50 (44.75)      | 56.00 (23.50)   | 26.00 (11.00)    | $\chi^2 = 41.37$ | $P = 1.000^{\text{NS}}$ |
|                        | Range (min-max) | 11.00 - 404.00 | 31.00 - 98.00 | 11.00 - 51.00 | $< 0.001^{\text{HS, a}}$ | $P < 0.001^{\text{HS}}$ |
| AST (U/L)              | Median (IQR) | 67.00 (68.25)      | 65.00 (37.50)   | 24.00 (12.50)    | $\chi^2 = 42.17$ | $P = 1.000^{\text{NS}}$ |
|                        | Range (min-max) | 12.00 - 534.00 | 23.00 - 243.00 | 12.00 - 49.00 | $< 0.001^{\text{HS, a}}$ | $P < 0.001^{\text{HS}}$ |
| Total bilirubin (mg/dL)| Median (IQR) | 1.65 (2.90)        | 2.10 (1.45)     | 0.80 (0.20)      | $\chi^2 = 34.79$ | $P = 0.213^{\text{NS}}$ |
|                        | Range (min-max) | 0.30 - 10.00 | 1.30 - 5.20 | 0.50 - 1.30 | $< 0.001^{\text{HS, a}}$ | $P < 0.001^{\text{HS}}$ |
| Albumin (g/dL)         | Median (IQR) | 3.30 (1.20)        | 2.60 (0.84)     | 4.30 (0.60)      | $\chi^2 = 56.69$ | $P = 0.153^{\text{NS}}$ |
|                        | Range (min-max) | 1.90 - 4.60 | 1.70 - 3.30 | 3.70 - 5.00 | $< 0.001^{\text{HS, a}}$ | $P < 0.001^{\text{HS}}$ |
| INR value              | Median (IQR) | 1.40 (0.60)        | 1.90 (0.70)     | 1.00 (0.20)      | $\chi^2 = 28.67$ | $P = 0.153^{\text{NS}}$ |
|                        | Range (min-max) | 0.90 - 3.10 | 1.00 - 3.10 | 0.90 - 1.30 | $< 0.001^{\text{HS, a}}$ | $P < 0.001^{\text{HS}}$ |
| Urea (mg/dL)           | Median (IQR) | 54.00 (22.00)      | 54.00 (44.50)   | 33.00 (12.50)    | $\chi^2 = 22.98$ | $P = 1.000^{\text{NS}}$ |
|                        | Range (min-max) | 21.00 - 190.00 | 12.00 - 98.00 | 17.00 - 53.00 | $< 0.001^{\text{HS, a}}$ | $P < 0.001^{\text{HS}}$ |
| Creatinine (mg/dL)     | Median (IQR) | 1.00 (0.53)        | 1.10 (0.70)     | 1.00 (0.20)      | $\chi^2 = 2.25$ | – |
|                        | Range (min-max) | 0.40 - 2.30 | 0.40 - 2.40 | 0.70 - 1.30 | 0.325 $^{\text{NS, a}}$ | – |
| RBS (mg/dL)            | Median (IQR) | 110.00 (47.25)     | 98.00 (44.00)   | 105.00 (27.00)   | $\chi^2 = 5.40$ | – |
|                        | Range (min-max) | 65.00 - 364.00 | 68.00 - 243.00 | 62.00 - 145.00 | $< 0.001^{\text{HS, a}}$ | – |
| AFP (ng/mL)            | Median (IQR) | 62.50 (226.25)     | 17.00 (16.50)   | – | $z = 4.58$ | – |
|                        | Range (min-max) | 5.40 - 151000.00 | 3.10 - 68.00 | – | $< 0.001^{\text{HS, a}}$ | – |

IQR, Interquartile range; NS, Non significant at P-value $\geq 0.05$; HS, Highly significant at P-value $< 0.01$; * Kruskal-Wallis test; * Mann-Whitney U test; *(*) Multiple pairwise comparisons adjusted by Bonferroni post hoc test; $P_x$, P-value for the difference between HCC and cirrhosis groups; $P_y$, P-value for the difference between HCC and control groups; $P_z$, P-value for the difference between cirrhosis and control groups.

Asian Pacific Journal of Cancer Prevention, Vol 21 2049
Frequency of EGF 61A>G SNP among studied groups and its risk effect

G allele showed statistical higher frequency in HCC group (63%) compared to cirrhotic patients (42%) and control group (38%) (p=0.005), with increased GG genotype in HCC group (40%) compared to cirrhotic patient group (16%) and control group (12%) (p=0.029).

Compared to cirrhotic patients, GG genotype was associated with significant increased risk of HCC compared to AA genotype with OR (95% CI) 5.71, (P=0.031). The G allele carried a highly significant risk of HCC compared with allele A OR (95% CI) 2.35, (P value =0.015). The variant G allele showed a significant association with HCC risk in the recessive model GG vs. AG+AA (P=0.036) rather than the dominant model GG +AG vs. AA (P=0.066)(Table 3). We couldn’t detect significant difference in genotype distribution and allele frequencies of EGF polymorphism between resectable and unresectable HCC patients (Table 4).

Table 3. Comparison of Genotypes Distribution and Allele Frequencies of EGF Polymorphism (61 A/G) in HCC versus Cirrhotic patients

| EGF Polymorphism 61 A/G | HCC (n = 50) | Cirrhosis (n = 25) | OR (95% CI) | P-value |
|------------------------|-------------|-------------------|-------------|---------|
| Genotypes [n (%)]      |             |                   |             |         |
| GG                     | 20 (40.0)   | 4 (16.0)          | 5.71 (1.30 - 25.03) | 0.031\(^a\) |
| AG                     | 23 (46.0)   | 13 (52.0)         | 2.02 (0.60 - 6.86)  | 0.255\(^b\) |
| AA                     | 7 (14.0)    | 8 (32.0)          | Ref.          | –       |
| Dominant model\(^a\)  |             |                   |             |         |
| GG +AG                 | 43 (86.0)   | 17 (68.0)         | 2.89 (0.91 - 9.22)  | 0.066\(^a\) |
| AA                     | 7 (14.0)    | 8 (32.0)          | Ref.          | –       |
| Recessive model\(^b\) |             |                   |             |         |
| GG                     | 20 (40.0)   | 4 (16.0)          | 3.50 (1.04 - 11.73) | 0.036\(^b\) |
| AG+AA                  | 30 (60.0)   | 21 (84.0)         | Ref.          | –       |
| Alleles [n (%)]        |             |                   |             |         |
| G                      | 63 (63.0)   | 21 (42.0)         | 2.35 (1.18 - 4.70)  | 0.015\(^b\) |
| A                      | 37 (37.0)   | 29 (58.0)         | Ref.          | –       |

\(^a\), Fisher’s Exact test; \(^b\), Pearson Chi-Square test; %, percent of genotype or allele within group-NS : Non significant at P-value \(\geq 0.05\); 1, Dominant model, (homozygous type + hybrid type) vs. wild type; 2, Recessive model, homozygous vs. (hybrid type+ wild type)

Table 4. Comparison of Genotype Distribution and Allele Frequencies of EGF Polymorphism (61 A/G) In resectable versus Unresectable HCC Patients

| EGF Polymorphism 61 A/G | Resectable HCC (n = 25) | Unresectable (n = 25) | OR (95% CI) | P-value |
|------------------------|--------------------------|-----------------------|-------------|---------|
| Genotypes [n (%)]      |                          |                       |             |         |
| GG                     | 8 (32.0)                 | 12 (48.0)             | 2.00 (0.35 - 11.44) | 0.662 NS,\(^a\) |
| AG                     | 13 (52.0)                | 10 (40.0)             | 1.03 (0.19 - 5.66)  | 1.000 NS,\(^a\) |
| AA                     | 4 (16.0)                 | 3 (12.0)              | Ref.          | –       |
| Dominant model\(^a\)  |                          |                       |             |         |
| GG +AG                 | 21 (84.0)                | 22 (88.0)             | 1.40 (0.28 – 7.00)  | 1.000 NS,\(^a\) |
| AA                     | 4 (16.0)                 | 3 (12.0)              | Ref.          | –       |
| Recessive model\(^b\) |                          |                       |             |         |
| GG                     | 8 (32.0)                 | 12 (48.0)             | 1.96 (0.62 - 6.19)  | 0.248 NS,\(^b\) |
| AG+AA                  | 17 (68.0)                | 13 (52.0)             | Ref.          | –       |
| Alleles [n (%)]        |                          |                       |             |         |
| G                      | 29 (58.0)                | 34 (68.0)             | 1.54 (0.68 - 3.49)  | 0.300 NS,\(^b\) |
| A                      | 21 (42.0)                | 16 (32.0)             | Ref.          | –       |

\(^a\), Fisher’s Exact test; \(^b\), Pearson Chi-Square test; %, percent of genotype or allele within group-NS : Non significant at P-value \(\geq 0.05\); 1, Dominant model, (homozygous type + hybrid type) vs. wild type; 2, Recessive model, homozygous vs. (hybrid type+ wild type)
Liver carcinogenesis is a complex and multi-factorial process, in which many signaling pathways could contribute to malignant transformation. EGF, through epidermal growth factor receptor (EGFR) acts as mitogen stimulating cellular proliferation and differentiation (Modica et al., 2019). Besides, EGF was suggested to contribute to the occurrence of inflammation and HCC (Berasain et al., 2009 and Huang et al., 2014).

EGF gene is 110 kb in length. It contains 24 exons, and is located on human chromosome 4q25. A single nucleotide polymorphism (SNP) 61A>G located in the 5' untranslated region influences the expression levels of EGF, where G/G genotype is associated with elevated EGF expression (Wu et al., 2013).

Our present study showed that A allele was more prevalent in the control group (62%). While, G allele was significantly dominant in HCC patients 63% in HCC patients compared to 42% in cirrhotic patients. G allele showed significantly high risk for HCC compared to cirrhosis (95% CI) 2.35 (P = 0.015).

These results proved that the G allele may have the risk of hepatocarcinogenesis, while A may be the protective allele. These results were similar to previous reports (Abu Dayyeh et al., 2011- Sun et al., 2015).

Table 5. Statistical Analysis of Biochemical and Clinical Parameters regarding Genotypes of EGF Polymorphism (61 A/G) in Resectable HCC Patients

| Parameters                  | EGF Polymorphism (61 A/G) | Significance test | Pairwise comparisons* |
|-----------------------------|---------------------------|-------------------|-----------------------|
| Age (year)                  |                           |                   |                       |
| Median (IQR)                | 55.50 (8.50)              | 61.00 (14.00)     | 47.50 (17.75)         |
| Range (min-max)             | 50.00 - 60.00             | 49.00 - 71.00     | 43.00 - 65.00         |
| Gender [n (%)]              |                           |                   |                       |
| Male                        | 7 (87.5)                  | 11 (84.6)         | 3 (75.0)              |
| Female                      | 1 (12.5)                  | 2 (15.4)          | 1 (25.0)              |
| EGF in tumor (T)            |                           |                   |                       |
| Mean ±SD                    | 200.00 ± 28.78            | 162.31 ± 30.86    | 152.50 ± 35.00        |
| Range (min-max)             | 160.00 - 250.00           | 110.00 - 210.00   | 110.00 - 190.00       |
| EGF in cirrhotic tissue (C) |                           |                   |                       |
| Mean ±SD                    | 162.50 ± 53.12            | 138.46 ± 53.52    | 140.00 ± 73.48        |
| Range (min-max)             | 80.00 - 220.00            | 60.00 - 220.00    | 40.00 - 200.00        |
| Foci size                   |                           |                   |                       |
| Median (IQR)                | 4.00 (1.13)               | 3.00 (1.00)       | 3.00 (2.00)           |
| Range (min-max)             | 3.00 - 5.00               | 2.00 - 5.00       | 2.00 - 4.00           |
| AFP                         |                           |                   |                       |
| Median (IQR)                | 49.50 (850.45)            | 36.00 (34.70)     | 33.00 (44.00)         |
| Range (min-max)             | 5.40 - 1327.00            | 11.50 - 65.00     | 32.00 - 90.00         |

%, percent within group; IQR, Interquartile range; *, Kruskal-Wallis test; †, Fisher’s exact test; ‡, ANOVA test; NS, Non significant at P-value ≥ 0.05; S, Significant at P-value < 0.05; *, Multiple pairwise comparisons adjusted by Tukey HSD Post hoc test; P, P-value for the difference between genotypes GG vs. AG; P1, P-value for the difference between genotypes GG vs. AA; P2, P-value for the difference between genotypes AG vs. AA.
Tanabe et al., (2008) demonstrated that the half-life of mRNA transcripts from the G allele was significantly longer than that from A allele. They concluded that the increased stability of transcribed mRNA could explain the increased risk with G allele. Similar results were reported by Suenaga et al, 2013.

However, a study conducted by Qi et al, 2009 conflicted our results. They failed to find a significant association between EGF61A/G SNP and risk of HCC(Qi et al, 2009).

In addition, a study directed by Gholidazadeh et al, 2017 on chronic HCV infected Iranian patients showed that frequency of the EGF 61A allele in HCC patients was significantly higher than the healthy controls (P value = 0.04). They proposed that the increased risk of HCC with different genotypes might be dependent on the population.

Regarding EGF protein expression in HCC tissue, our present study showed that there was higher concentration of EGF in the tumor tissue (T) (200.00 ± 28.78) in patients with GG genotype compared to AG genotype (162.31 ± 30.86) and AA genotype (152.50 ± 35.00), p= 0.019. This means that functional polymorphism in the EGF gene can modify its protein production.

These results matched with Li et al., (2010) immunohistochemical results of HCC liver tissue. They showed that samples with the GG genotype expressed EGF protein more than those with the AG genotype. In addition, a study conducted by Liu et al., (2018) demonstrated that the expression of EGF in HCCs was significantly higher compared with that in normal tissues, which indicates that EGF is highly expressed in HCCs microenvironment. Furthermore, higher level of EGF was significantly associated with higher grade, which suggest that EGF may stimulate progression of HCCs.

To conclude, in the present study, EGF gene polymorphism 61A/G was associated with increased HCC risk(patients with G/G genotype having more risk than A/G and AA). This is confirmed by increased EGF gene expression in tumor tissue of G/G genotype. This could increase the risk of HCC in cirrhotic HCV Egyptian patients. Thus, patients carrying the risk alleles should be closely followed up for early diagnosis and better outcome of treatment.

Acknowledgments

All authors contributed equally. There were no competing interests.

Authors contribution to work

Conception of the study, Ibrahim Baghdadi; design of the study, Khaled Abu Ella; Investigation, Ahmed Elshaarawy and Mary Naguib; Methodology, Ahmed Elshaarawy, Hala S. El-Rebey and Mary Naguib; Formal analysis, ElsayedElshayb; writing original draft, Mohamed M. Elhoseeny, Mary Naguib and Ali Nada; Writing- review and editing, Ibrahim Baghdadi, Khaled Abu Ella, Ahmed Elshaarawy, ElsayedElshayb, Hala S. El-Rebey, Mohamed M. Elhoseeny, Mary Naguib and Ali Nada

Ethical approval and informed consent

Study was conducted according to the Declaration of Helsinki. Protocol of the study was approved by Institution Review Board of National Liver Institute Menoufiya University. All participants provided written informed consent.

References

Abbas E, Shaker O, Abd El Aziz G, et al (2012). Epidermal growth factor gene polymorphism 61A/G in patients with chronic liver disease for early detection of hepatocellular carcinoma: a pilot study. Eur J Gastroenterol Hepatol, 24, 458-63.

Abu Dayyeh BK, Yang M, Fuchs BC, et al (2011). A functional polymorphism in the epidermal growth factor gene is associated with risk for hepatocellular carcinoma. Gastroenterology, 141, 141-9.

Almeida LO, Custódio AC, Santos MJ, et al (2010). The A61G EGF polymorphism is associated with development of extraaxial nervous system tumors but not with overall survival. Cancer Genet Cyto genet, 198, 15-21.

Amend KL, Elder JT, Tomsho LP, et al (2004). EGF gene polymorphism and the risk of incident primary melanoma. Cancer Res, 64, 2668-72.

BerasainC, Perugorria MJ, Latasa MU, et al (2009). The epidermal growth factor receptor: a link between inflammation and liver cancer. Exp Biol Med (Maywood), 7, 713–25.

GholizadehM, Khosravi A, Torabian P, et al (2017). Association of the epidermal growth factor gene +61A/G polymorphism with hepatocellular carcinoma in an Iranian population. Gastroenterol Hepatol Bed Bench, 10, 284-8.

Huang P, Xu X, Wang L, et al (2014). The role of EGF-EGFR signalling pathway in hepatocellular carcinoma inflammatory microenvironment. J Cell Mol Med, 18, 218-30.

Jiang G, Yu K, Shao L, et al (2015). Association between epidermal growth factor gene +61A/G polymorphism and the risk of hepatocellular carcinoma: a meta-analysis based on 16 studies. BMC Cancer, 15, 314.

Lavanchy D, Kane M (2016). Global Epidemiology of Hepatitis B Virus Infection. Molecular and Translational Medicine. Springer International Publishing, pp 187-203.

Li Y, Xie Q, Lu F, et al (2010). Association between epidermal growth factor 61A/G polymorphism and hepatocellular carcinoma susceptibility in Chinese patients. Liver Int, 30, 112-8.

Liu Z, Chen D, Ning F, et al (2018). EGF is highly expressed in hepatocellular carcinoma (HCC) and promotes motility of HCC cells via fibronectin. J Cell Biochem, 119, 4170-83.

ModicaTME, Dituri F, Mancarella S, et al (2019).Calcium regulates HCC proliferation as well as EGFR recycling/degradation and could be a new therapeutic target in HCC. Onco Targets Ther, 13, 1805-12.
Sun S, Jin GJ, Zhao Y, et al (2015). Association between the epidermal growth factor 61*A/G polymorphism and hepatocellular carcinoma risk: a meta-analysis. *Asian Pac J Cancer Prev*, **16**, 3009-14.

Tanabe KK, Lemoine A, Finkelstein DM, et al (2008). Epidermal growth factor gene functional polymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis. *JAMA*, **299**, 53-60.

Thrift AP, El-Serag HB and Kanwal F (2017). Global epidemiology and burden of HCV infection and HCV-related disease. *Nat Rev Gastroenterol Hepatol*, **14**, 122-32.

Waked I, Doss W, El-Sayed M, et al (2014). The current and future disease burden of chronic hepatitis C virus infection in Egypt. *Arab J Gastroenterol*, **15**, 45–52.

Wu D, Wu Y, Zhang X, et al (2013). Lack of association between EGF +61A>G polymorphism and melanoma susceptibility in Caucasians: a HuGE review and meta-analysis. *Gene*, **25**, 359-66.

Xu W, Li Y, Wang X, et al (2010). Association between EGF promoter polymorphisms and cancer risk: a meta-analysis. *Med Oncol*, **27**, 1389–97.

Yuan JM, Fan Y, Ognjanovic S, et al (2013). Genetic polymorphisms of epidermal growth factor in relation to risk of hepatocellular carcinoma: two case-control studies. *BMC Gastroenterol*, **13**, 32.

Zhang YM, Cao C, Liang K (2010) Genetic polymorphism of epidermal growth factor 61A>G and cancer risk: a meta-analysis. *Cancer Epidemiol*, **34**, 150-6.

Zhong JH, You XM, Gong WF, et al (2012). Epidermal growth factor gene polymorphism and risk of hepatocellular carcinoma: a meta-analysis. *PLoS One*, **7**, e32159.

Zhong JH, You XM, Gong WF, et al (2012). Epidermal growth factor gene polymorphism and risk of hepatocellular carcinoma: A Meta-Analysis. *PLoS One*, **7**, e32159.

This work is licensed under a Creative Commons Attribution-Non Commercial 4.0 International License.